Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 9/20 | 0.47 |
| ▸ | BTK | Q06187 | 7/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104736 | 0.90 | BTK (0.49) | RIPK2BTKSRCABL1EGFR | |
| SCHEMBL30582611 | 0.90 | BTK (0.49) | RIPK2BTKSRCABL1EGFR | |
| SCHEMBL30582634 | 0.90 | RIPK2 (0.46) | RIPK2BTKSRCABL1EGFR | |
| SCHEMBL30582549 | 0.86 | RIPK2 (0.49) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL26107090 | 0.86 | RIPK2 (0.49) | RIPK2SRCABL1EGFRABL2 | |
| SCHEMBL26109460 | 0.81 | RIPK2 (0.43) | RIPK2BTKSRCABL1EGFR | |
| SCHEMBL22676206 | 0.73 | ITK (0.60) | BTKKDR | |
| SCHEMBL30582530 | 0.73 | BTK (0.48) | RIPK2BTKSRCABL1EGFR | |
| SCHEMBL26109362 | 0.73 | BTK (0.48) | RIPK2BTKSRCABL1EGFR | |
| SCHEMBL30582631 | 0.72 | PDE2A (0.43) | RIPK2BTKSRCABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |